^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    opugotamig olatansine (IMGN-151)

    i
    Other names: IMGN-151, IMGN151
    Company:
    AbbVie
    Drug class:
    Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate
    Related drugs:
    4ms
    A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (clinicaltrials.gov)
    P2, N=377, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • opugotamig olatansine (IMGN-151)
    6ms
    A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (clinicaltrials.gov)
    P2, N=350, Not yet recruiting, AbbVie
    New P2 trial • Adverse events
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • opugotamig olatansine (IMGN-151)
    11ms
    IMGN151-1001: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (clinicaltrials.gov)
    P1, N=423, Recruiting, AbbVie | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2024 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    opugotamig olatansine (IMGN-151)
    1year
    First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (clinicaltrials.gov)
    P1, N=423, Recruiting, ImmunoGen, Inc. | N=227 --> 423
    Enrollment change
    |
    FOLR1 ( Folate receptor alpha )
    |
    opugotamig olatansine (IMGN-151)
    over1year
    First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (clinicaltrials.gov)
    P1, N=227, Recruiting, ImmunoGen, Inc. | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    opugotamig olatansine (IMGN-151)